Greetings from the Research Lab! In our bi-monthly publication, we share the latest news  from the field, recent findings from our clinical studies, and stories about  the  people of Napa Medical Research Foundation.

Welcome to the Board: Conrad Hewitt

A Napa resident for over 20 years, Mr. Hewitt has been involved in helping hospitals, clinics, educational and financial institutions for many years. He brings extensive leadership experience and financial and community involvement skills to the Foundation. Mr. Hewitt looks forward to helping NMRF expand its mission to deliver leading edge regenerative medical solutions to the Napa Valley and the medical community in general.  Read More

Introducing the new NMRF Research Lab

We are excited to announce the completion of a new research lab facility dedicated to leading the field in proving the performance capability of key regenerative medicine treatments.  
With the dedicated assistance of biomedical laboratory consultant Ryan Dregalla, PhD, Dregalla Medical Technologies, the NMRF will greatly expand the scope and capacity of Dr Bodor’s research. Located in Suite C of the Wellness Center in Napa, the lab serves to complement current and future clinical studies, provide publication-grade data to support clinical findings, and further innovations in the diagnosis and treatment of orthopedic, musculoskeletal, and neurologic conditions and diseases.  Read More

PRP: History, Mechanism of Action, Preparation and Clinical Applications

By Dr. Marko Bodor, Ryan Dregalla, PhD, and Yvette Uribe, BA
Excerpt from Chapter 8 in the forthcoming publication,Essentials of Regenerative Medicine in Interventional Pain Management.
History
Platelet Rich Plasma (PRP) was first described for clinical use in 1999 to enhance osseointegration for tooth implants well after specific individual growth factors had already been identified for healing of various wound and injury types. The therapeutic importance of platelets became clear when they became better characterized, acting as reservoirs for a wide array of bioactive factors, growth factors, adhesive proteins, coagulation factors, cytokines and chemokines released in the presence of appropriate stimuli and orchestrated in the progression of wound repair. Hence, it was logical to assume that if platelets and their bioactive factors were concentrated and delivered to an injury site, the healing process could be enhanced and expedited.

Current Research Study Updates

Carpometacarpal (CMC) Joint Bone Marrow Aspirate Concentrate (BMAC) Outcome Case Study

Dr. Bodor is initiating the first control study to compare the effects of Bone Marrow Aspirate Concentrate (BMAC) to Platelet-Rich Plasma (PRP) for treatment of conditions affecting the thumb CMC joint. In some cases, Dr. Bodor has treated patients with BMAC instead of PRP and has begun to formulate the hypothesis that BMAC could be more effective. The study will determine how and why BMAC works through a 40 patient randomized control study – the first of its kind in the world.

Sever’s Disease Study

40 children have successfully finished the specialized 12-week program with all experiencing marked improvement after the first two weeks of treatment.  A randomized control study is in progress with 4 patients enrolled and the need for 12 more subjects to complete the study.  All patients will ultimately receive the newly developed treatment. Dr. Bodor will publish a paper on the Sever’s Disease Study in The American Journal of Sports Medicine.

Cervical Facet Study

The initial hypothesis stated that use of ultrasound guidance for injections into the cervical facet joints would result in greater accuracy and the delivery of a full dose of biologic agent. The study findings, reflecting a 95 – 100% accuracy rate, were shared and analyzed by Dr, Naveen Murthy of the Mayo Clinic and prove the effectiveness of this minimally invasive, less costly ultrasound-guided cervical facet injection technique.We anticipate publication of these impressive results in October 2017.